J. Hoppe, A. Holderied, U. Schönermarck, V. Vielhauer, Hans-Joachim Anders, M. Fischereder
{"title":"Medikamenteninduzierte CYP-Induktion als Therapie der Tacrolimus-Intoxikation","authors":"J. Hoppe, A. Holderied, U. Schönermarck, V. Vielhauer, Hans-Joachim Anders, M. Fischereder","doi":"10.5414/nhx02295","DOIUrl":"https://doi.org/10.5414/nhx02295","url":null,"abstract":"","PeriodicalId":274783,"journal":{"name":"Nieren- und Hochdruckkrankheiten","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126054422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Hyponatriämie – was tun?","authors":"M. Alscher","doi":"10.5414/nhx02280","DOIUrl":"https://doi.org/10.5414/nhx02280","url":null,"abstract":"","PeriodicalId":274783,"journal":{"name":"Nieren- und Hochdruckkrankheiten","volume":"75 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114807777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Diagnose und Steuerung der Progression der chronischen Nierenerkrankung","authors":"D.A. Torozan, A. Sellier, S. Schunk","doi":"10.5414/nhx02299","DOIUrl":"https://doi.org/10.5414/nhx02299","url":null,"abstract":"","PeriodicalId":274783,"journal":{"name":"Nieren- und Hochdruckkrankheiten","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114431734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
*Erweiterte Fassung des Vortrags auf der 14. Jahrestagung der Deutschen Gesellschaft fϋ r Nephrologie, 8. Oktober 2022, Estrel Congress Center Berlin. Xenotransplantation: Immunologische und infektiologische Barrieren — Was wurde überwunden, was ist noch zu tun? Der Mangel an menschlichen Spenderorganen führte zur Entwicklung der Xenotransplantation, als Spendertiere wurden aus verschiedenen Gründen Schweine ausgewählt. Zwei Haupthorden sind zu überwinden, bevor die Xenotransplantation zur alltäglichen Therapieform wird: die immunologische Abstoßung, vor allem die hyperakute Abstoßung, und die potenzielle Übertragung zoonotischer Mikroorganismen des Schweins, wobei zoonotisch bedeutet, dass sie in der Lage sind, im Empfänger eine Krankheit auszulösen. Zur Überwindung der Abstoßung wurden mehrfach gentechnisch modifizierte Schweine gezüchtet, bei denen Gene des Schweins ausgeknockt bzw. Gene des Menschen eingebracht wurden. In präklinischen Studien mit nicht-humanen Primaten konnte eine beachtliche Überlebensdauer von Zellen und Organen derart gentechnisch modifizierter Tiere erreicht werden, zum Beispiel von Inselzellen zur Behandlung von Diabetes sowie von Nieren und Herzen. Zur Verhinderung der Übertragung von Mikroorganismen des Schweins, vor allem von Viren, auf den Empfänger, wurden sensitive Methoden zum Nachweis und entsprechende Programme zur Eliminierung dieser Viren entwickelt. Im Januar 2022 wurde in Baltimore das Herz eines 10-fach modifizierten Schweins auf einen Patienten übertragen, dabei wurde ein neues Immunsuppressivum eingesetzt. Der Patient überlebte 2 Monate mit dem Schweineherz, was als Erfolg eingestuft werden kann. Allerdings wurde dabei ein Schweinevirus übertragen, das mit hoher Wahrscheinlichkeit zum Tod des Patienten beitrug. Bei Anwendung optimaler Testmethoden kann eine derartige Übertragung jedoch problemlos vermieden und die Überlebensdauer des Organs verlängert werden.
{"title":"Xenotransplantation: Immunologische und infektiologische Barrieren – Was wurde überwunden, was ist noch zu tun?","authors":"J. Denner","doi":"10.5414/nhx02289","DOIUrl":"https://doi.org/10.5414/nhx02289","url":null,"abstract":"*Erweiterte Fassung des Vortrags auf der 14. Jahrestagung der Deutschen Gesellschaft fϋ r Nephrologie, 8. Oktober 2022, Estrel Congress Center Berlin. Xenotransplantation: Immunologische und infektiologische Barrieren — Was wurde überwunden, was ist noch zu tun? Der Mangel an menschlichen Spenderorganen führte zur Entwicklung der Xenotransplantation, als Spendertiere wurden aus verschiedenen Gründen Schweine ausgewählt. Zwei Haupthorden sind zu überwinden, bevor die Xenotransplantation zur alltäglichen Therapieform wird: die immunologische Abstoßung, vor allem die hyperakute Abstoßung, und die potenzielle Übertragung zoonotischer Mikroorganismen des Schweins, wobei zoonotisch bedeutet, dass sie in der Lage sind, im Empfänger eine Krankheit auszulösen. Zur Überwindung der Abstoßung wurden mehrfach gentechnisch modifizierte Schweine gezüchtet, bei denen Gene des Schweins ausgeknockt bzw. Gene des Menschen eingebracht wurden. In präklinischen Studien mit nicht-humanen Primaten konnte eine beachtliche Überlebensdauer von Zellen und Organen derart gentechnisch modifizierter Tiere erreicht werden, zum Beispiel von Inselzellen zur Behandlung von Diabetes sowie von Nieren und Herzen. Zur Verhinderung der Übertragung von Mikroorganismen des Schweins, vor allem von Viren, auf den Empfänger, wurden sensitive Methoden zum Nachweis und entsprechende Programme zur Eliminierung dieser Viren entwickelt. Im Januar 2022 wurde in Baltimore das Herz eines 10-fach modifizierten Schweins auf einen Patienten übertragen, dabei wurde ein neues Immunsuppressivum eingesetzt. Der Patient überlebte 2 Monate mit dem Schweineherz, was als Erfolg eingestuft werden kann. Allerdings wurde dabei ein Schweinevirus übertragen, das mit hoher Wahrscheinlichkeit zum Tod des Patienten beitrug. Bei Anwendung optimaler Testmethoden kann eine derartige Übertragung jedoch problemlos vermieden und die Überlebensdauer des Organs verlängert werden.","PeriodicalId":274783,"journal":{"name":"Nieren- und Hochdruckkrankheiten","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131286589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: A new generation of vaccine technology platform has been developed to combat the COVID- 19 pandemic, the mRNA vaccine. The EMA granted the Pfizer- BioNTech COVID-19 vaccine an emergency use authorization in December 2020 with limited clinical experience, especially in the pediatric population. Method(s): Here, we present a case-report of a 17-yearold girl, who was vaccinated with the mRNA-COVID vaccine in October 2021, and developed a gross hematuria and proteinuria the day after the vaccination. Result(s): The patient presented at our outpatient clinic three days after the vaccination with new-onset hematuria and proteinuria. Up to this date, she had no former known medical conditions and the family history was negative regarding kidney diseases. We excluded nephrolithiasis, autoimmune glomerulonephritis and urinary tract infection as causes. The laboratory chemistry of the kidney was within normal range. The proteinuria dissolved spontaneously, and a microhematuria persisted. One day after the second dose of Cominarty in November 2021, the gross hematuria with proteinuria relapsed. A treatment with an ACE-inhibitor did not have any effect on the proteinuria. At this point, only a few casereports of patients with a comparable clinical course, especially from Japan, were published. In suspicion of a vaccine-triggered nephritis we started a prednisolon therapy which dissolved the proteinuria and induced a regression of the haematuria to a minimal stage. Conclusion(s): Within the last year, the medical community has gained more insights concerning mRNA vaccines. There is growing evidence, that mRNA vaccines can trigger de novo or relapse IgA nephropathy. But more systematic research and long-term evaluation is desirable to elucidate the underling pathophysiology as well as the influence on kidney survival of affected patients in the future. Furthermore, patient education should incorporate the risk of hematuria and proteinuria in children when applying mRNA vaccines.
{"title":"54. Jahrestagung der Gesellschaft für Pädiatrische Nephrologie (GPN); 3. – 6. Mai 2023, Marburg","authors":"S. Weber","doi":"10.5414/nhx02301","DOIUrl":"https://doi.org/10.5414/nhx02301","url":null,"abstract":"Objective: A new generation of vaccine technology platform has been developed to combat the COVID- 19 pandemic, the mRNA vaccine. The EMA granted the Pfizer- BioNTech COVID-19 vaccine an emergency use authorization in December 2020 with limited clinical experience, especially in the pediatric population. Method(s): Here, we present a case-report of a 17-yearold girl, who was vaccinated with the mRNA-COVID vaccine in October 2021, and developed a gross hematuria and proteinuria the day after the vaccination. Result(s): The patient presented at our outpatient clinic three days after the vaccination with new-onset hematuria and proteinuria. Up to this date, she had no former known medical conditions and the family history was negative regarding kidney diseases. We excluded nephrolithiasis, autoimmune glomerulonephritis and urinary tract infection as causes. The laboratory chemistry of the kidney was within normal range. The proteinuria dissolved spontaneously, and a microhematuria persisted. One day after the second dose of Cominarty in November 2021, the gross hematuria with proteinuria relapsed. A treatment with an ACE-inhibitor did not have any effect on the proteinuria. At this point, only a few casereports of patients with a comparable clinical course, especially from Japan, were published. In suspicion of a vaccine-triggered nephritis we started a prednisolon therapy which dissolved the proteinuria and induced a regression of the haematuria to a minimal stage. Conclusion(s): Within the last year, the medical community has gained more insights concerning mRNA vaccines. There is growing evidence, that mRNA vaccines can trigger de novo or relapse IgA nephropathy. But more systematic research and long-term evaluation is desirable to elucidate the underling pathophysiology as well as the influence on kidney survival of affected patients in the future. Furthermore, patient education should incorporate the risk of hematuria and proteinuria in children when applying mRNA vaccines.","PeriodicalId":274783,"journal":{"name":"Nieren- und Hochdruckkrankheiten","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128582206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"CTEPH – interventionelle und andere Therapiemöglichkeiten","authors":"M.S.D. Adameit, S. Guth, C. Wiedenroth","doi":"10.5414/atx02670","DOIUrl":"https://doi.org/10.5414/atx02670","url":null,"abstract":"","PeriodicalId":274783,"journal":{"name":"Nieren- und Hochdruckkrankheiten","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124824529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karl-Patrik Kresoja, A. R. Schöber, S. Rosch, H. Thiele, P. Lurz, K. Rommel
{"title":"Pulmonale Hypertonie bei Patienten mit Herzinsuffizienz und erhaltener linksventrikulärer Funktion (HFpEF)","authors":"Karl-Patrik Kresoja, A. R. Schöber, S. Rosch, H. Thiele, P. Lurz, K. Rommel","doi":"10.5414/atx02674","DOIUrl":"https://doi.org/10.5414/atx02674","url":null,"abstract":"","PeriodicalId":274783,"journal":{"name":"Nieren- und Hochdruckkrankheiten","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133492303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Zach, A. Beblo, A.M. Chitroceanu, F. Edelmann, A. Eggers
{"title":"Spiroergometrie bei pulmonaler Hypertonie und Herzinsuffizienz","authors":"V. Zach, A. Beblo, A.M. Chitroceanu, F. Edelmann, A. Eggers","doi":"10.5414/atx02685","DOIUrl":"https://doi.org/10.5414/atx02685","url":null,"abstract":"","PeriodicalId":274783,"journal":{"name":"Nieren- und Hochdruckkrankheiten","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131293082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Kardiale Sarkoidose – Diagnostik und Therapie Update 2022","authors":"D. Skowasch, L. Biener, C. Grohé, C. Pizarro","doi":"10.5414/atx2660","DOIUrl":"https://doi.org/10.5414/atx2660","url":null,"abstract":"","PeriodicalId":274783,"journal":{"name":"Nieren- und Hochdruckkrankheiten","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121565479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Herz-Lungen-Interaktion bei COPD: Pneumo meets Kardio","authors":"P. Alter, C. Vogelmeier, R. Jörres","doi":"10.5414/atx02647","DOIUrl":"https://doi.org/10.5414/atx02647","url":null,"abstract":"","PeriodicalId":274783,"journal":{"name":"Nieren- und Hochdruckkrankheiten","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130387385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：